Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

ONO PHARMACEUTICAL CO., LTD. (4528)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

ONO PHARMACEUTICAL CO., LTD. : Voluntary adoption of International Financial Reporting Standards (IFRS)(64.9KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/13/2013 | 01:15pm CEST

May 13, 2013
ONO PHARMACEUTICAL CO., LTD. Corporate Communications
TEL: +81-6-6263-5670

Voluntary adoption of International Financial Reporting Standards (IFRS)

Ono Pharmaceutical Co., Ltd. (Chuo-ku, Osaka, President: Gyo Sagara) resolved at the meeting of Board of Directors held today that IFRS is to be adopted to its group's consolidated financial reports and consolidated calculation documents ending on March 31st, 2014. Its financial reports and documents used to be based on Japan Generally Accepted Accounting Principles (Japan GAAP).
Our group has been facilitating business development such as research and development and licensing activities globally in the U.S.A, Europe and Asian regions as well as in Japan. Additionally foreign investors account for about 30 % of the total shareholders as of March 31st,
2013, which has shown large proportion of foreign investors from the past. With these situations considered, we have decided to voluntarily adopt IFRS to disclose financial information based on international standards, improve comparability and enhance convenience of stakeholders
including shareholders, investors and business partners.
Ref: <Schedule of disclosure of financial information in association with the change of accounting standards>

May 2013

Flash Report and consolidated calculation document ending on

March 31st, 2013

Japan GAAP

June 2013

Annual Report ending on March 31st, 2013

Japan GAAP

Financial information on 1Q to 3Q ending on March 31st, 2014

Japan GAAP

May 2014

Flash Report and consolidated calculation document ending on

March 31st, 2014

IFRS

June 2014

Annual Report ending on March 31st, 2014

IFRS

Consolidated Financial Forecast in Fiscal Year ended March 31, 2014 (FY2013) under IFRS

Table below shows trial IFRS calculation of the consolidated forecast for the fiscal year ending March 31, 2014, disclosed today.

(Billion JPY)

IFRS (1)

J-GAAP (2)

Difference ((1) - (2))

Net sales

146.3

148.3

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
06/22ONO PHARMACEUTICAL : Notice of Resolutions Passed at The 70th Ordinary General S..
PU
06/05ONO PHARMACEUTICAL : Opdivo Plus Chemotherapy Showed Improved Progression-Free S..
PU
06/05ONO PHARMACEUTICAL : Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior..
PU
06/05ONO PHARMACEUTICAL : Array BioPharma Announces Additional Median Overall Surviva..
PU
06/04ONO PHARMACEUTICAL : Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimuma..
PU
05/31Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Cons..
AQ
05/30ONO PHARMACEUTICAL : Announcement on Establishment of Immune-mediated Inflammato..
PU
05/25ONO PHARMACEUTICAL : and BMSKK Receive Approval for Opdivo® and Yervoy® Combinat..
PU
05/25ONO PHARMACEUTICAL : Notice to Convene the 70th Ordinary General Shareholders' M..
PU
05/07ONO PHARMACEUTICAL : European Medicines Agency Validates Bristol-Myers Squibb&rs..
PU
More news
News from SeekingAlpha
04/303 THINGS IN BIOTECH, APRIL 29 : Bristol-Myers Widens, Ono Takes On Pheo, BrainSt.. 
03/23Alzheon Files To Raise $80 Million In U.S. IPO 
03/14Ono Pharma exercises option for Merus Biclonics technology for autoimmune bis.. 
2017Ono Pharmaceutical Needs To Reinvest Its Windfall 
2017YOUR DAILY PHARMA SCOOP : Axovant's Promised Upside, Gilead's Whistleblower Trou.. 
Financials ( JPY)
Sales 2019 279 B
EBIT 2019 -
Net income 2019 53 113 M
Finance 2019 92 785 M
Yield 2019 1,71%
P/E ratio 2019 26,18
P/E ratio 2020 21,15
EV / Sales 2019 4,90x
EV / Sales 2020 4,34x
Capitalization 1 462 B
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 3 218  JPY
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director & Executive Vice President
Isao Ono Director & Managing Executive Officer
Kei Sano Director & Senior Executive Officer